Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect

被引:15
|
作者
Heiat, Mohammad [1 ]
Yeganeh, Hamid Hashemi [2 ]
Alavian, Seyed Moayed [1 ]
Rezaie, Ehsan [3 ]
机构
[1] Baqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran 1435916471, Iran
[2] Tarbiat Modares Univ, Fac Biol Sci, Dept Biochem, Tehran 14115111, Iran
[3] Baqiyatallah Univ Med Sci, Syst Biol & Poisonings Inst, Mol Biol Res Ctr, Tehran 1435916471, Iran
关键词
immunotoxin; hepatocellular carcinoma; targeted therapy; liver cancer; drug targeting; GAMMA-GLUTAMYL-TRANSFERASE; ANTI-MESOTHELIN IMMUNOTOXIN; RECOMBINANT IMMUNOTOXINS; CANCER-CELLS; PSEUDOMONAS EXOTOXIN; MONOCLONAL-ANTIBODY; BETA-CATENIN; E-CADHERIN; EXPRESSION; RECEPTOR;
D O I
10.3390/toxins13100719
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. Therefore, fighting against such cancer is reasonable. Chemotherapy drugs are sometimes inefficient and often accompanied by undesirable side effects for patients. On the other hand, the emergence of chemoresistant HCC emphasizes the need for a new high-efficiency treatment strategy. Immunotoxins are armed and rigorous targeting agents that can purposefully kill cancer cells. Unlike traditional chemotherapeutics, immunotoxins because of targeted toxicity, insignificant cross-resistance, easy production, and other favorable properties can be ideal candidates against HCC. In this review, the characteristics of proper HCC-specific biomarkers for immunotoxin targeting were dissected. After that, the first to last immunotoxins developed for the treatment of liver cancer were discussed. So, by reviewing the strengths and weaknesses of these immunotoxins, we attempted to provide keynotes for designing an optimal immunotoxin against HCC.</p>
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Hepatocellular Carcinoma Immunotherapy
    Sperandio, Rubens Copia
    Pestana, Roberto Carmagnani
    Miyamura, Beatriz Viesser
    Kaseb, Ahmed O.
    ANNUAL REVIEW OF MEDICINE, 2022, 73 : 267 - 278
  • [22] Immunotherapy of hepatocellular carcinoma
    Geissler, M
    Mohr, L
    Blum, HE
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2001, 126 (51-52) : 1464 - 1466
  • [23] Immunotherapy for hepatocellular carcinoma
    Yin Zongyi
    Li Xiaowu
    CANCER LETTERS, 2020, 470 : 8 - 17
  • [24] Immunotherapy in Hepatocellular Carcinoma
    Claudia A. M. Fulgenzi
    Thomas Talbot
    Sam M. Murray
    Marianna Silletta
    Bruno Vincenzi
    Alessio Cortellini
    David J. Pinato
    Current Treatment Options in Oncology, 2021, 22
  • [25] Immunotherapy in hepatocellular carcinoma
    Jones, RL
    Young, LS
    Adams, DH
    LANCET, 2000, 356 (9232): : 784 - 785
  • [26] Immunotherapy for hepatocellular carcinoma
    Wang Xiaoxia
    Lu Jun
    中华医学杂志英文版, 2024, 137 (15)
  • [27] Immunotherapy of hepatocellular carcinoma
    Butterfield, LH
    Ribas, A
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (02) : 123 - 133
  • [28] Immunotherapy of hepatocellular carcinoma
    Greten, Tim
    Korangy, Firouzeh
    INFLAMMATION RESEARCH, 2007, 56 : S146 - S147
  • [29] Immunotherapy of Hepatocellular Carcinoma
    Heinrich, Bernd
    Czauderna, Carolin
    Marquardt, Jens U.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (05) : 292 - 297
  • [30] Immunotherapy of hepatocellular carcinoma
    Greten, Tim F.
    Manns, Michael P.
    Korangy, Firouzeh
    JOURNAL OF HEPATOLOGY, 2006, 45 (06) : 868 - 878